Floatz logo

Young Til

Metastatic Endocrine Tumors/ Neuroendocrine Tumors

National Cancer Institute (NCI)Cell therapyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Metastatic Endocrine Tumors/ Neuroendocrine Tumors cohort.

Asset / SponsorPhaseRating
Pembrolizumab
National Cancer Institute (NCI)
Phase 2CCC
Fludarabine
National Cancer Institute (NCI)
Phase 2CCC
Cyclophosphamide
National Cancer Institute (NCI)
Phase 2CCC

Same molecule, other indications

Young Til is also rated in:

skin cancerDormant
B
Indicative ·
57 / 100
View asset →
metastatic melanomaDormant
B
Indicative ·
57 / 100
View asset →
oropharyngeal carcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →